Wellbeing Digital to Participate at this Years’ Wonderland Miami Conference

Wellbeing Digital Sciences Inc. (NEO: MEDI | OTC: KONEF | (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that Najla Guthrie, CEO, will participate at this years’ Wonderland Miami Conference taking place on November 3 to November 5, 2022 at the Mana Wynwood Convention Centre.

Wonderland is one of the world’s largest conferences in the psychedelic medicine sector. It provides an opportunity to discover the world of psychedelic medicine, and is attended by some of the leading founders, investors, therapists, practitioners, researchers, thought leaders, innovators, and media from around the globe.

Najla Guthrie will participate on 3 panels:

November 4 at 9:30 a.m. ET- The Politics of Psychedelic Medicine – Will the evidence from psychedelic medicine research move politicians to develop a more rational and progressive drug policy?

November 4 at 5:00 p.m. ET- Building the Last Mile – Building centers of excellence for next generation therapies.

November 5 at 12:20 p.m. ET- Ketamine for Pain & Depression from Randomized Clinical Trials to Real Life Evidence – What does the current data show for using ketamine for pain and depression? The panel will explore how to connect trial results with personalized ketamine treatments.

Register to attend here.

For more information about the conference, or to schedule a one-on-one meeting with Wellbeing management team, please send an email to Natalie Dolphin at ndolphin@wellbeingdigital.co.

Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research. Its mission is supported by a network of North American clinics that provide forward-thinking therapies and other types of treatment to patients as well as through a contract research organization that offers clinical trials services to clients pursuing drug development.